|
All Releases
 |
Achillion Announces First-in-Human Dosing of ACH-1625 for Treatment of Hepatitis C
Jun 29, 2009
|
12.9 KB |
|
| |
NEW HAVEN, Conn., Jun 29, 2009 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that the Company has begun dosing in a Phase I clinical trial of ACH-1625, a protease inhibitor...
|
|
Achillion to Present At Upcoming Conferences
Jun 2, 2009
|
9.3 KB |
|
| |
NEW HAVEN, Conn., Jun 2, 2009 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, President and Chief Executive Officer, will give a corporate overview...
|
|
Achillion Reports First Quarter Financial Results and Provides Pipeline Update
May 15, 2009
|
14.3 KB |
|
| |
NEW HAVEN, Conn., May 15, 2009 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three months ended March 31, 2009. For the first quarter of 2009, the ...
|
|
Achillion Granted U.S. Patent for NS4A Antagonists in Hepatitis C
Apr 16, 2009
|
11.9 KB |
|
| |
NEW HAVEN, Conn., Apr 16, 2009 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that the U.S. Patent & Trademark Office has granted Achillion U.S. Patent No. 7,476,686 related...
|
|
Achillion to Present At the Canaccord Adams Hepatitis C Conference
Apr 3, 2009
|
9.4 KB |
|
| |
NEW HAVEN, Conn., Apr 3, 2009 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Mary Kay Fenton, Vice President and Chief Financial Officer, will give a corporate presenta...
|
|
Achillion Reports 2008 Fourth Quarter and Year-End Financial Results
Mar 25, 2009
|
17.1 KB |
|
| |
Mar 25, 2009 (GlobeNewswire via COMTEX News Network) --
Provides 2009 Guidance and Program Update
Conference Call to Begin At 4:30 pm Eastern Time Today
NEW HAVEN, Conn., March 25, 2009 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecul...
|
|
Achillion Pharmaceuticals To Host Fourth Quarter and Fiscal Year 2008 Financial Results Conference Call on Wednesday, March 25, 2009
Mar 24, 2009
|
11.1 KB |
|
| |
NEW HAVEN, Conn., March 24, 2009 -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that the Company will release financial results for the fourth quarter and...
|
|
Webcast Alert: Lippert/Heilshorn Life Sciences Conference Presentation (Achillion Pharmaceuticals, Inc.)
Mar 23, 2009
|
9.8 KB |
|
| |
NEW YORK, Mar 23, 2009 (BUSINESS WIRE) -- Achillion Pharmaceuticals, Inc. (ACHN) announces the following Webcast:
What: Lippert/Heilshorn Life Sciences Conference Presentation
When: March 26, 2009 @ 1:30 PM Eastern
Where: http://www.investorcalendar.com/ClientPage.asp?ID=142727How: Live over the Internet -- Simply log on to the web at the addres...
|
|
Achillion to Present At the Cowen & Company 29th Annual Healthcare Conference
Mar 11, 2009
|
9.4 KB |
|
| |
NEW HAVEN, Conn., Mar 11, 2009 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, President and Chief Executive Officer, will give a corporate present...
|
|
Achillion to Present At the 11th Annual BIO CEO & Investor Conference
Feb 5, 2009
|
9.5 KB |
|
| |
NEW HAVEN, Conn., Feb 5, 2009 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael Kishbauch, President and Chief Executive Officer, will give a corporate presentati...
|
|
Achillion Announces Appointment of New Head of Business Development
Jan 7, 2009
|
11.3 KB |
|
| |
NEW HAVEN, Conn., Jan 7, 2009 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced the appointment of Joseph Truitt as Vice President of Business Development and Chief Commercial ...
|
|
Achillion Appoints Dr. Dennis Liotta to Board of Directors
Dec 18, 2008
|
11.3 KB |
|
| |
NEW HAVEN, Conn., Dec 18, 2008 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced the appointment of Dennis C. Liotta, Ph.D. to its Board of Directors. Dr. Liotta will fill the ...
|
|
Achillion to Present At Lazard Capital Markets 5th Annual Healthcare Conference
Nov 17, 2008
|
8.9 KB |
|
| |
NEW HAVEN, Conn., Nov 17, 2008 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, announced that Michael D. Kishbauch, President and Chief Executive Officer of Achillion, will be presenting a c...
|
|
Achillion Reports Third Quarter 2008 Financial Results
Oct 28, 2008
|
13.9 KB |
|
| |
NEW HAVEN, Conn., Oct 28, 2008 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the quarter and nine months ended September 30, 2008.
For the nine mon...
|
|
Data From Achillion's Antibacterial and HIV Programs Presented At the 2008 ICAAC/IDSA Joint Meeting
Oct 27, 2008
|
15.0 KB |
|
| |
Oct 27, 2008 (GlobeNewswire via COMTEX News Network) --
Four Posters Highlight Unique Mechanism and Broad-Spectrum
Antibacterial Activity of ACH-702
Unique Elvucitabine Activity Profile and 48-Week Phase 2 Results
Featured in Oral Presentation
NEW HAVEN, Conn., Oct. 27, 2008 (GLOBE ...
|
|
Achillion Appoints Nicholas Simon to Board of Directors
Aug 20, 2008
|
10.5 KB |
|
| |
NEW HAVEN, Conn., Aug 20, 2008 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced the appointment of Nicholas Simon to its Board of Directors. Mr. Simon, who is Managing Directo...
|
|
Achillion Reports Second Quarter 2008 Financial Results
Aug 12, 2008
|
15.6 KB |
|
| |
NEW HAVEN, Conn., Aug 12, 2008 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the quarter and six months ended June 30, 2008.
For the six months end...
|
|
Achillion to Present At Canaccord Adams Global Growth Conference
Aug 12, 2008
|
8.9 KB |
|
| |
NEW HAVEN, Conn., Aug 12, 2008 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, announced that Michael D. Kishbauch, President and Chief Executive Officer of Achillion, will be presenting a c...
|
|
Achillion Announces Private Placement Financing for up to $41.5 Million
Aug 6, 2008
|
13.2 KB |
|
| |
, Aug 6, 2008 (PrimeNewswire via COMTEX News Network) -- Proceeds to Fund Expanding Pipeline of Infectious Disease Candidates - - Company to Hold Conference Call to Discuss Second Quarter Results August 12 -
NEW HAVEN, Conn., Aug. 6, 2008 (PRIME NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and developmen...
|
|
Achillion Announces Additional Positive Top-Line Phase 2 Data for Elvucitabine
Jun 9, 2008
|
11.9 KB |
|
| |
NEW HAVEN, Conn., Jun 9, 2008 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced additional positive safety and efficacy results from its ongoing Phase 2 trial studying elvucita...
|
|
|
= add release to Briefcase |